<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hutson, LeAnne</style></author><author><style face="normal" font="default" size="100%">Obuekwe, Joy</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acute Myeloid Leukemia – Down Syndrome: A Case Study from a Children’s Hospital</style></title><secondary-title><style face="normal" font="default" size="100%">American Society for Clinical Laboratory Science</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><doi><style  face="normal" font="default" size="100%">10.29074/ascls.2020002840</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Congenital conditions like Down syndrome have been associated with increased risk for clonal disorders that affect megakaryocytic lineage. The World Health Organization has classified acute myeloid leukemia – Down syndrome (ML-DS) as a specific subtype of acute myeloid leukemia. Studies have shown that children with ML-DS have a better prognosis than children without Down syndrome with a long-term survival rate of 74%–91%. One possible explanation for this differentiation is that the megakaryoblast cells in ML-DS have increased sensitivity to cytotoxic drugs like cytarabine-based therapy. This has been attributed to the GATA1-mutant isoform decreased expression of cytidine deaminase and the overexpression of the cystathionine-β–synthase, a chromosome 21–localized gene present in ML-DS megakaryoblast cells. This case study followed the course of diagnosis and treatment of a 17-month-old patient with ML-DS. GATA1 mutation was confirmed in this case, and flow cytometry identified a megakaryoblast population expressing cluster differentiation markers of CD13, CD33, CD34, CD7, CD36, CD41, CD61, CD71, and CD117 in approximately 43.5% of the sample. As a result of the flow cytometry, physicians confirmed ML-DS as the diagnosis. The patient received 2 rounds of a chemotherapy treatment that included a combination chemotherapy regime with intrathecal chemotherapy to prevent relapse. Within 1 month of treatment, the patient was in remission and has remained with negative minimal residual disease to date.</style></abstract></record></records></xml>